Current drug strategies for the treatment and control of schistosomiasis

References

• WHO. Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021–2030. Geneva: World Health Organization; 2022.
   Google Scholar
• Menezes CA, Montresor LC, Jangola STG, et al. FioSchisto’s expert perspective on implementing WHO guidelines for schistosomiasis control and transmission elimination in Brazil. Front Immunol. 2023;14:1268998. doi: 10.3389/fimmu.2023.1268998
   PubMed Web of Science ®Google Scholar
• WHO. Fact sheet. Geneva:WHO; [updated 2023 Feb 1; cited 2024 Oct 3]. Schistosomiasis. Available from: https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
   Google Scholar
• Nelwan ML. Schistosomiasis: Life Cycle, Diagnosis, and Control. Curr Ther Res. 2019;91:5–9. doi: 10.1016/j.curtheres.2019.06.001
   PubMed Web of Science ®Google Scholar
• Xu R, Feng J, Hong Y, et al. A novel colloidal gold immunochromatography assay strip for the diagnosis of schistosomiasis japonica in domestic animals. Infect Dis Poverty. 2017;6(1):84. doi: 10.1186/s40249-017-0297-z
   PubMedGoogle Scholar
• Boissier J, Grech-Angelini S, Webster BL, et al. Outbreak of urogenital schistosomiasis in Corsica (France): an epidemiological case study. Lancet Infect Dis. 2016;16(8):971–979. doi: 10.1016/S1473-3099(16)00175-4
   PubMed Web of Science ®Google Scholar
• Barsoum RS, Esmat G, El-Baz T. Human schistosomiasis: clinical perspective: review. J Adv Res. 2013;4(5):433–444. doi: 10.1016/j.jare.2013.01.005
   PubMedGoogle Scholar
• Vale N, Gouveia MJ, Rinaldi G, et al. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. 2017;61(5):10.1128/aac.02582–16. doi: 10.1128/aac.02582-16
   PubMed Web of Science ®Google Scholar
• Waechtler A, Cezanne B, Maillard D, et al. Praziquantel – 50 years of research. ChemMedchem. 2023;18(12):e202300154. doi: 10.1002/cmdc.202300154
   PubMed Web of Science ®Google Scholar
• Kramer CV, Zhang F, Sinclair D, et al. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2014;2014(8). CD000053. doi: 10.1002/14651858.CD000053.pub3
   Google Scholar
• Danso‐Appiah A, Olliaro PL, Donegan S, et al. Drugs for treating schistosoma mansoni infection. Cochrane Database Syst Rev. 2013;2013:CD000528. doi: 10.1002/14651858.CD000528.pub2
   PubMedGoogle Scholar
• Fukushige M, Chase-Topping M, Woolhouse MEJ, et al. Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): a systematic review and meta-analysis of factors influence its efficacy. PLoS Negl Trop Dis. 2021;15(3):e0009189. doi: 10.1371/journal.pntd.0009189
   PubMed Web of Science ®Google Scholar
• Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasites Vectors. 2017;10(1):47. doi: 10.1186/s13071-016-1958-7
   PubMedGoogle Scholar
• Zwang J, Olliaro PL, Jones MK. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis—A meta-analysis of comparative and Non-comparative clinical Trials. PLoS Negl Trop Dis. 2014;8(11):e3286. doi: 10.1371/journal.pntd.0003286
   PubMed Web of Science ®Google Scholar
• Yu Q-F, Zhang J-Y, Sun M-T, et al. In vivo praziquantel efficacy of Schistosoma japonicum over time: A systematic review and meta-analysis. Acta Trop. 2021;222:106048. doi: 10.1016/j.actatropica.2021.106048
   PubMed Web of Science ®Google Scholar
• Andrade G, Bertsch DJ, Gazzinelli A, et al. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2017;11(2):e0005372. doi: 10.1371/journal.pntd.0005372
   PubMed Web of Science ®Google Scholar
• Lim RM, Arme TM, Pedersen AB, et al. Defining schistosomiasis hotspots based on literature and shareholder interviews. Trends Parasitol. 2023;39(12):1032–1049. doi: 10.1016/j.pt.2023.09.006
   PubMed Web of Science ®Google Scholar
• Chami GF, Kabatereine NB, Tukahebwa EM, et al. The division of labour between community medicine distributors influences the reach of mass drug administration: a cross-sectional study in rural Uganda. Remais JV, editor. PLoS Negl Trop Dis. 2019;13(9):e0007685. doi: 10.1371/journal.pntd.0007685
   PubMed Web of Science ®Google Scholar
• King CH, Binder S, Shen Y, et al. SCORE studies on the impact of drug treatment on morbidity due to schistosoma mansoni and schistosoma haematobium infection. Am J Trop Med Hyg. 2020;103(1_Suppl):30–35. doi: 10.4269/ajtmh.19-0830
   PubMed Web of Science ®Google Scholar
• Binder S, Campbell CH, Castleman JD, et al. Lessons learned in conducting Mass drug administration for schistosomiasis control and measuring coverage in an operational research setting. Am J Trop Med Hyg. 2020;103(1_Suppl):105–113. doi: 10.4269/ajtmh.19-0789
   PubMed Web of Science ®Google Scholar
• WHO. News. Schistosomiasis And Soil-Transmitted Helminthiases: Treating Millions Of People, Despite The Pandemic. Geneva: WHO; [updated 2021 Dec 8; cited 2024 Oct 3]. Available from: https://www.who.int/news/item/08-12-2021-schistosomiasis-and-soil-transmitted-helminthiases-treating-millions-of-people-despite-the-pandemic
   Google Scholar
• Cribb DM, Clarke NE, Doi SAR, et al. Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2019;13(10):e0007808. doi: 10.1371/journal.pntd.0007808
   PubMed Web of Science ®Google Scholar
• Olliaro PL, Coulibaly JT, Garba A, et al. Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: an individual participant data meta-analysis. Montresor A, editor. PLoS Negl Trop Dis. 2020;14(6):e0008277. doi: 10.1371/journal.pntd.0008277
   PubMed Web of Science ®Google Scholar
• Eneanya OA, Gankpala L, Goss CW, et al. Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia. Acta Trop. 2022;231:106437. doi: 10.1016/j.actatropica.2022.106437
   PubMed Web of Science ®Google Scholar
• Wang W, Li H-J, Qu G-L, et al. Is there a reduced sensitivity of dihydroartemisinin against praziquantel-resistant Schistosoma japonicum? Parasitol Res. 2014;113(1):223–228. doi: 10.1007/s00436-013-3647-1
   PubMed Web of Science ®Google Scholar
• Gower CM, Gouvras AN, Lamberton PHL, et al. Population genetic structure of schistosoma mansoni and schistosoma haematobium from across six sub-Saharan African countries: implications for epidemiology, evolution and control. Acta Trop. 2013;128(2):261–274. doi: 10.1016/j.actatropica.2012.09.014
   PubMed Web of Science ®Google Scholar
• Zacharia A, Mushi V, Makene T, et al. A systematic review and meta-analysis on the rate of human schistosomiasis reinfection. PLoS One. 2020;15(12):e0243224. doi: 10.1371/journal.pone.0243224
   PubMed Web of Science ®Google Scholar
• Colley DG, Secor WE. Immunology of human schistosomiasis. Parasite Immunol. 2014;36:347–357. doi: 10.1111/pim.12087
   PubMed Web of Science ®Google Scholar
• Anyubaga SB, Shallangwa GA, Uzairu A, et al. Chemo-informatics applications in the design of novel 7-keto-sempervirol derivatives as SmCB1 inhibitors with potential for treatment of schistosomiasis. Heliyon. 2024;10(1):e23115. doi: 10.1016/j.heliyon.2023.e23115
   PubMed Web of Science ®Google Scholar
• Da Silva VBR, BRKL C, De Oliveira JF, et al. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine. Bioorg Med Chem. 2017;25(13):3259–3277. doi: 10.1016/j.bmc.2017.04.031
   PubMed Web of Science ®Google Scholar
• Zdesenko G, Mutapi F, Gilleard JS. Drug metabolism and pharmacokinetics of praziquantel: a review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. PLoS Negl Trop Dis. 2020;14(9):e0008649. doi: 10.1371/journal.pntd.0008649
   PubMed Web of Science ®Google Scholar
• Kovač J, Vargas M, Keiser J. In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium. Parasites Vectors. 2017;10(1):365. doi: 10.1186/s13071-017-2293-3
   PubMedGoogle Scholar
• Friedrich L, Park S-K, Ballard P, et al. Metabolism of (R)-praziquantel versus the activation of a parasite transient receptor potential Melastatin Ion Channel. ChemMedchem. 2023;18(18):e202300140. doi: 10.1002/cmdc.202300140
   PubMed Web of Science ®Google Scholar
• Kasago FM, Häberli C, Keiser J, et al. Design, synthesis and evaluation of praziquantel Analogues and new molecular hybrids as potential antimalarial and anti-schistosomal agents. Mol. 2023;28(13):5184. doi: 10.3390/molecules28135184
   PubMed Web of Science ®Google Scholar
• Xu J, Dong L-L, Sun H, et al. Small change, big difference: a promising praziquantel derivative designated P96 with broad-spectrum antischistosomal activity for chemotherapy of schistosomiasis japonica. PLoS Negl Trop Dis. 2023;17(7):e0011215. doi: 10.1371/journal.pntd.0011215
   PubMed Web of Science ®Google Scholar
• Sprague DJ, Kaethner M, Park S-K, et al. The Anthelmintic activity of praziquantel analogs correlates with structure–activity relationships at TRPMPZQ orthologs. ACS Med Chem Lett. 2023;14(11):1537–1543. doi: 10.1021/acsmedchemlett.3c00350
   PubMed Web of Science ®Google Scholar
• Falcoz C, Guzy S, Kovač J, et al. R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with schistosoma mansoni and S. haematobium and Lao adults infected with opisthorchis viverrini. J Pharmacokinet Pharmacodyn. 2022;49(3):293–310. doi: 10.1007/s10928-021-09791-8
   PubMed Web of Science ®Google Scholar
• Mahende MK, Huber E, Kourany-Lefoll E, et al. Comparative palatability of orally disintegrating tablets (ODTs) of praziquantel (L-PZQ and rac-PZQ) versus current PZQ tablet in African children: a randomized, single-blind, crossover study. PLoS Negl Trop Dis. 2021;15(6):e0007370. doi: 10.1371/journal.pntd.0007370
   PubMed Web of Science ®Google Scholar
• Guzman M, Rugel A, Tarpley RS, et al. Molecular basis for hycanthone drug action in schistosome parasites. Mol Biochem Parasitol. 2020;236:111257. doi: 10.1016/j.molbiopara.2020.111257
   PubMed Web of Science ®Google Scholar
• El-Sayad M, Abu Helw S, El-Taweel H, et al. Antiparasitic Activity of Mirazid, Myrrh Total Oil and Nitazoxanide Compared to Praziquantel on Schistosoma mansoni: Scanning Electron Microscopic Study. Iran j parasitol. 2017;12:446–452.
   PubMed Web of Science ®Google Scholar
• Elbakry KA, Abdelaziz MM. Myrrh and artesunate modulate some Th1 and Th2 cytokines secretion in Schistosoma mansoni infected mice. Cent Eur J Immunol. 2016;2:138–142. doi: 10.5114/ceji.2016.60986
   Google Scholar
• Sharaf O, Khalil A. The effects of mirazid fractions on the viability of schistosomula of schistosoma mansoni: an in vitro study. J Egypt Soc Parasitol. 2016;46(2):245–252. doi: 10.12816/0031631
   PubMedGoogle Scholar
• Lotfy WM, Nageh AM, Hussein NA, et al. Application and evaluation of a molecular approach for detection of the schistosomicidal effect of Mirazid® (myrrh) in the murine model. J Adv Res. 2013;4(6):563–567. doi: 10.1016/j.jare.2012.08.012
   PubMedGoogle Scholar
• El-Nagar DM, Al Olayan EM, Aloufi AS, et al. The potent effect of silymarin combination with praziquantel or mirazid for schistosoma mansoni treatment in infected male Swiss albino mice. Trop Biomed. 2021;38(1):22–27. doi: 10.47665/tb.38.1.004
   PubMed Web of Science ®Google Scholar
• Trainor-Moss S, Mutapi F. Schistosomiasis therapeutics: whats in the pipeline? Expert Rev Clin Pharmacol. 2016;9(2):157–160. doi: 10.1586/17512433.2015.1102051
   PubMed Web of Science ®Google Scholar
• Cheuka PM, Mayoka G, Mutai P, et al. The role of natural products in drug discovery and development against neglected tropical diseases. Mol J Synth Chem Nat Prod Chem. 2016;22(1):58. doi: 10.3390/molecules22010058
   Google Scholar
• Rugel AR, Guzman MA, Taylor AB, et al. Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum? Int J Parasitol Drugs Drug Resist. 2020;13:8–15. doi: 10.1016/j.ijpddr.2020.04.001
   PubMed Web of Science ®Google Scholar
• Guzman MA, Rugel A, Alwan SN, et al. Schistosome sulfotransferases: mode of action, expression and localization. Pharmaceutics. 2022;14(7):1416. doi: 10.3390/pharmaceutics14071416
   PubMed Web of Science ®Google Scholar
• Taylor AB, Roberts KM, Cao X, et al. Structural and enzymatic insights into species-specific resistance to schistosome parasite drug therapy. J Biol Chem. 2017;292(27):11154–11164. doi: 10.1074/jbc.M116.766527
   PubMed Web of Science ®Google Scholar
• Valentim CLL, Cioli D, Chevalier FD, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science. 2013;342(6164):1385–1389. doi: 10.1126/science.1243106
   PubMed Web of Science ®Google Scholar
• Chevalier FD, Le Clec’h W, McDew-White M, et al. Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment. PLoS Pathog. 2019;15(10):e1007881. doi: 10.1371/journal.ppat.1007881
   PubMed Web of Science ®Google Scholar
• Taylor AB, Pica-Mattoccia L, Polcaro CM, et al. Structural and functional characterization of the enantiomers of the antischistosomal drug Oxamniquine. PLoS Negl Trop Dis. 2015;9(10):e0004132. doi: 10.1371/journal.pntd.0004132
   PubMed Web of Science ®Google Scholar
• Hess J, Keiser J, Gasser G. Toward organometallic antischistosomal drug candidates. Future Med Chem. 2015;7(6):821–830. doi: 10.4155/fmc.15.22
   PubMed Web of Science ®Google Scholar
• Hess J, Panic G, Patra M, et al. Ferrocenyl, Ruthenocenyl, and benzyl oxamniquine derivatives with Cross-species activity against schistosoma mansoni and schistosoma haematobium. ACS Infect Dis. 2017;3(9):645–652. doi: 10.1021/acsinfecdis.7b00054
   PubMed Web of Science ®Google Scholar
• Buchter V, Hess J, Gasser G, et al. Assessment of tegumental damage to schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy. Parasites Vectors. 2018;11(1):580. doi: 10.1186/s13071-018-3132-x
   PubMedGoogle Scholar
• Buchter V, Ong YC, Mouvet F, et al. Multidisciplinary preclinical investigations on three oxamniquine analogues as new drug candidates for schistosomiasis**. Chem – Eur J. 2020;26(66):15232–15241. doi: 10.1002/chem.202002856
   PubMed Web of Science ®Google Scholar
• Rugel A, Tarpley RS, Lopez A, et al. Design, synthesis, and characterization of novel small molecules as broad range antischistosomal agents. ACS Med Chem Lett. 2018;9(10):967–973. doi: 10.1021/acsmedchemlett.8b00257
   PubMed Web of Science ®Google Scholar
• LoVerde PT, Alwan SN, Taylor AB, et al. Rational approach to drug discovery for human schistosomiasis. Int J Parasitol Drugs Drug Resist. 2021;16:140–147. doi: 10.1016/j.ijpddr.2021.05.002
   PubMed Web of Science ®Google Scholar
• Alwan SN, Taylor AB, Rhodes J, et al. Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. PLoS Pathog. 2023;19(7):e1011018. doi: 10.1371/journal.ppat.1011018
   PubMed Web of Science ®Google Scholar
• Reimers N, Homann A, Höschler B, et al. Drug-induced exposure of schistosoma mansoni antigens SmCD59a and SmKK7. PLoS Negl Trop Dis. 2015;9(3):e0003593. doi: 10.1371/journal.pntd.0003593
   PubMed Web of Science ®Google Scholar
• Vimieiro ACS, Araújo N, Katz N, et al. Schistogram changes after administration of antischistosomal drugs in mice at the early phase of schistosoma mansoni infection. Mem Inst Oswaldo Cruz. 2013;108(7):881–886. doi: 10.1590/0074-0276130135
   PubMed Web of Science ®Google Scholar
• Toth K, Alwan S, Khan S, et al. Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments. Int J Parasitol Drugs Drug Resist. 2023;21:65–73. doi: 10.1016/j.ijpddr.2023.01.003
   PubMed Web of Science ®Google Scholar
• Ramamoorthi R, Graef KM, Dent J. Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline. Future Med Chem. 2015;7(6):727–735. doi: 10.4155/fmc.15.26
   PubMed Web of Science ®Google Scholar
• Ho WE, Peh HY, Chan TK, et al. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014;142(1):126–139. doi: 10.1016/j.pharmthera.2013.12.001
   PubMed Web of Science ®Google Scholar
• Raffetin A, Bruneel F, Roussel C, et al. Use of artesunate in non-malarial indications. Médecine Mal Infect. 2018;48(4):238–249. doi: 10.1016/j.medmal.2018.01.004
   PubMed Web of Science ®Google Scholar
• Lam NS, Long X, Su X, et al. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis. Pharmacol Res. 2018;133:77–100. doi: 10.1016/j.phrs.2018.04.025
   PubMed Web of Science ®Google Scholar
• Du Toit A, Van Der Kooy F. Artemisia afra, a controversial herbal remedy or a treasure trove of new drugs? J Ethnopharmacol. 2019;244:112127. doi: 10.1016/j.jep.2019.112127
   PubMed Web of Science ®Google Scholar
• Keiser J, Silué KD, Adiossan LK, et al. Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial. Garba A, editor. PLoS Negl Trop Dis. 2014;8:e2975. doi: 10.1371/journal.pntd.0002975
   PubMed Web of Science ®Google Scholar
• Elmorshedy H, Tanner M, Bergquist RN, et al. Prophylactic effect of artemether on human schistosomiasis mansoni among Egyptian children: a randomized controlled trial. Acta Trop. 2016;158:52–58. doi: 10.1016/j.actatropica.2016.02.015
   PubMed Web of Science ®Google Scholar
• Zoleko-Manego R, Okwu DG, Handrich C, et al. Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: a non-randomised event-monitoring study. Downs JA, editor. PLoS Negl Trop Dis. 2022;16:e0010899. doi: 10.1371/journal.pntd.0010899
   PubMed Web of Science ®Google Scholar
• Saeed MEM, Krishna S, Greten HJ, et al. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res. 2016;110:216–226. doi: 10.1016/j.phrs.2016.02.017
   PubMed Web of Science ®Google Scholar
• Yuan Y, Lv X, Wu Y, et al. Mining host candidate regulators of schistosomiasis-induced liver fibrosis in response to artesunate therapy through transcriptomics approach. Cwiklinski K, editor. PLoS Negl Trop Dis. 2023;17:e0011626. doi: 10.1371/journal.pntd.0011626
   PubMed Web of Science ®Google Scholar
• Abdin AA, Ashour DS, Shoheib ZS. Artesunate effect on schistosome thioredoxin glutathione reductase and cytochrome c peroxidase as new molecular targets in schistosoma mansoni-infected mice. Biomed Environ Sci BES. 2013;26(12):953–961. doi: 10.3967/bes2013.030
   PubMed Web of Science ®Google Scholar
• Mbanzulu KM, Zanga JK, Mukendi JPK, et al. The impact of artesunate-amodiaquine on schistosoma mansoni infection among children infected by plasmodium in rural area of Lemfu, kongo central, Democratic Republic of the Congo. Biomed Res Int. 2018;2018:1–7. doi: 10.1155/2018/3487183
   Web of Science ®Google Scholar
• Wu J, Wang X, Chiu FCK, et al. Structure–activity relationship of antischistosomal ozonide carboxylic acids. J Med Chem. 2020;63(7):3723–3736. doi: 10.1021/acs.jmedchem.0c00069
   PubMed Web of Science ®Google Scholar
• Corrêa SDAP, De Oliveira RN, Mendes TMF, et al. In vitro and in vivo evaluation of six artemisinin derivatives against Schistosoma mansoni. Parasitol Res. 2019;118(2):505–516. doi: 10.1007/s00436-018-6188-9
   PubMed Web of Science ®Google Scholar
• El-Beshbishi SN, El Bardicy S, Tadros M, et al. Efficacy of artemisinin–naphthoquine phosphate against schistosoma haematobium adult flukes: dose–effect relationship and tegumental alterations. J Helminthol. 2019;93(4):513–518. doi: 10.1017/S0022149X18000421
   PubMed Web of Science ®Google Scholar
• Li H-J, Wang W, Li Y-Z, et al. In vivo activity of dihydroartemisinin against Schistosoma mansoni schistosomula in mice. Southeast Asian J Trop Med Public Health. 2013;44:379–387.
   PubMed Web of Science ®Google Scholar
• Mnkugwe RH, Minzi O, Kinung’hi S, et al. Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: a randomized, non-inferiority clinical trial. Basáñez M-G, editor. PLoS Negl Trop Dis. 2020;14:e0008619. doi: 10.1371/journal.pntd.0008619
   PubMed Web of Science ®Google Scholar
• Talaam KK, Inaoka DK, Hatta T, et al. Mitochondria as a potential target for the development of prophylactic and therapeutic drugs against schistosoma mansoni infection. Antimicrob Agents Chemother. 2021;65(10):e00418–21. doi: 10.1128/AAC.00418-21
   PubMed Web of Science ®Google Scholar
• Xiao S, Qiao C, Xue J, et al. Mefloquine in combination with hemin causes severe damage to adult schistosoma japonicum in vitro. Acta Trop. 2014;131:71–78. doi: 10.1016/j.actatropica.2013.12.005
   PubMed Web of Science ®Google Scholar
• Mitsui Y. Comparison of the in vitro effects of one-day exposure to amodiaquine and praziquantel on schistosoma mansoni adult worm pairs. Trop Med Health. 2014;42:87–92. doi: 10.2149/tmh.2013-28
   PubMedGoogle Scholar
• Koehne E, Zander N, Rodi M, et al. Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma. Gobert G, editor. PLoS Negl Trop Dis. 2021;15(6):e0009511. doi: 10.1371/journal.pntd.0009511
   PubMed Web of Science ®Google Scholar
• Mossallam SF, Amer EI, El-Faham MH. Efficacy of SynriamTM, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of schistosoma mansoni. Acta Trop. 2015;143:36–46. doi: 10.1016/j.actatropica.2014.12.005
   PubMed Web of Science ®Google Scholar
• Eissa MM, Mossallam SF, Amer EI, et al. Repositioning of chlorambucil as a potential anti-schistosomal agent. Acta Trop. 2017;166:58–66. doi: 10.1016/j.actatropica.2016.11.006
   PubMed Web of Science ®Google Scholar
• El-Moslemany RM, Eissa MM, Ramadan AA, et al. Miltefosine lipid nanocapsules: intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. Acta Trop. 2016;159:142–148. doi: 10.1016/j.actatropica.2016.03.038
   PubMed Web of Science ®Google Scholar
• Eissa MM, El-Moslemany RM, Ramadan AA, et al. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One. 2015;10(11):e0141788. doi: 10.1371/journal.pone.0141788
   PubMed Web of Science ®Google Scholar
• Eissa MM, El-Azzouni MZ, El-Khordagui LK, et al. Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni. Acta Trop. 2020;212:105714. doi: 10.1016/j.actatropica.2020.105714
   PubMed Web of Science ®Google Scholar
• Lee EF, Fairlie WD. Repurposing apoptosis-inducing cancer drugs to treat schistosomiasis. Future Med Chem. 2015;7(6):707–711.
   PubMed Web of Science ®Google Scholar
• Gelmedin V, Dissous C, Grevelding CG. Re-positioning protein-kinase inhibitors against schistosomiasis. Future Med Chem. 2015;7(6):737–752. doi: 10.4155/fmc.15.31
   PubMed Web of Science ®Google Scholar
• Mokosch AS, Gerbig S, Grevelding CG, et al. High-resolution AP-SMALDI MSI as a tool for drug imaging in Schistosoma mansoni. Anal Bioanal Chem. 2021;413(10):2755–2766. doi: 10.1007/s00216-021-03230-w
   PubMed Web of Science ®Google Scholar
• Giuliani S, Silva AC, Borba JVVB, et al. Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents. Briggs JM, editor. PLoS Comput Biol. 2018;14:e1006515. doi: 10.1371/journal.pcbi.1006515
   PubMed Web of Science ®Google Scholar
• Chua MJ, Arnold MSJ, Xu W, et al. Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and schistosoma parasite growth. Int J Parasitol Drugs Drug Resist. 2017;7:42–50. doi: 10.1016/j.ijpddr.2016.12.005
   PubMed Web of Science ®Google Scholar
• Cowan N, Keiser J. Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni. Parasites Vectors. 2015;8(1):417. doi: 10.1186/s13071-015-1023-y
   PubMedGoogle Scholar
• Herrera-Martínez M, Orozco-Samperio E, Montaño S, et al. Vorinostat as potential antiparasitic drug. Eur Rev Med Pharmacol Sci. 2020;24:7521–7528. doi: 10.26355/eurrev_202007_21909
   Web of Science ®Google Scholar
• Ehrenkaufer G, Li P, Stebbins EE, et al. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. Acosta-Serrano A, editor. PLoS Negl Trop Dis. 2020;14:e0008150. doi: 10.1371/journal.pntd.0008150
   PubMed Web of Science ®Google Scholar
• Oliveira RN, Corrêa SAP, Vieira KM, et al. In vitro schistosomicidal activity of tamoxifen and its effectiveness in a murine model of schistosomiasis at a single dose. Parasitol Res. 2019;118(5):1625–1631. doi: 10.1007/s00436-019-06259-0
   PubMed Web of Science ®Google Scholar
• Silva TC, Mengarda AC, Silva BC, et al. New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies. Future Med Chem. 2021;13(11):945–957. doi: 10.4155/fmc-2020-0311
   PubMed Web of Science ®Google Scholar
• Pereira Moreira B, Weber MHW, Haeberlein S, et al. Drug repurposing and De Novo drug Discovery of Protein Kinase Inhibitors as new drugs against schistosomiasis. Molecules. 2022;27(4):1414. doi: 10.3390/molecules27041414
   PubMed Web of Science ®Google Scholar
• Ryan KT, Wheeler NJ, Kamara IK, et al. Phenotypic profiling of macrocyclic lactones on parasitic schistosoma flatworms. Antimicrob Agents Chemother. 2023;67(2):e01230–22. doi: 10.1128/aac.01230-22
   PubMed Web of Science ®Google Scholar
• Siddiqui AJ, Khan MF, Hamadou WS, et al. Molecular docking and dynamics simulation revealed ivermectin as potential drug against Schistosoma-associated bladder cancer targeting protein signaling: computational drug repositioning approach. Medicina (Mex). 2021;57(10):1058. doi: 10.3390/medicina57101058
   Google Scholar
• Katz N, Araújo N, Coelho PMZ, et al. Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of schistosomiasis. J Antibiot (Tokyo). 2017;70(5):680–684. doi: 10.1038/ja.2017.31
   PubMed Web of Science ®Google Scholar
• Vicente B, López-Abán J, Chaccour J, et al. The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental schistosoma mansoni infection in mice. Sci Rep. 2021;11(1):4476. doi: 10.1038/s41598-021-84009-y
   PubMed Web of Science ®Google Scholar
• Fiamma M, Longoni SS, Siddig EE, et al. Multi-parasite infection in an immigrant from Ghana: potential for new epidemic foci. J Infect Dev Ctries. 2020;14(11):1344–1348. doi: 10.3855/jidc.13151
   PubMed Web of Science ®Google Scholar
• Karpstein T, Pasche V, Häberli C, et al. Evaluation of emodepside in laboratory models of human intestinal nematode and schistosome infections. Parasites Vectors. 2019;12(1):226. doi: 10.1186/s13071-019-3476-x
   PubMedGoogle Scholar
• Roquini DB, Cogo RM, Mengarda AC, et al. Promethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepatomegaly, and splenomegaly in a schistosomiasis animal model. Antimicrob Agents Chemother. 2019;63(12):e01208–19. doi: 10.1128/AAC.01208-19
   PubMed Web of Science ®Google Scholar
• Xavier RP, Mengarda AC, Silva MP, et al. H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies. Parasites Vectors. 2020;13(1):278. doi: 10.1186/s13071-020-04140-z
   PubMed Web of Science ®Google Scholar
• Sarhan RM, Thabet HS, Nazeer JT, et al. The impact of cinnarizine and griseofulvin on juvenile and adult stages of schistosoma mansoni. J Helminthol. 2019;94:e41. doi: 10.1017/S0022149X19000178
   PubMed Web of Science ®Google Scholar
• Lago EM, Silva MP, Queiroz TG, et al. Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. EBioMedicine. 2019;43:370–379. doi: 10.1016/j.ebiom.2019.04.029
   PubMed Web of Science ®Google Scholar
• Abou-El-Naga IF, El-Temsahy MM, Mogahed NMFH, et al. Effect of celecoxib against different developmental stages of experimental schistosoma mansoni infection. Acta Trop. 2021;218:105891. doi: 10.1016/j.actatropica.2021.105891
   PubMed Web of Science ®Google Scholar
• Guerra RA, Silva MP, Silva TC, et al. In vitro and in vivo studies of spironolactone as an antischistosomal drug capable of clinical repurposing. Antimicrob Agents Chemother. 2019;63(3):e01722–18. doi: 10.1128/AAC.01722-18
   PubMed Web of Science ®Google Scholar
• El Hady WE A, GA E-E, et al. The idiosyncratic efficacy of spironolactone-loaded PLGA nanoparticles against murine intestinal schistosomiasis. Int J Nanomedicine. 2023;18:987–1005. doi: 10.2147/IJN.S389449
   PubMed Web of Science ®Google Scholar
• Weeks JC, Roberts WM, Leasure C, et al. Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelmintic drugs capable of clinical repurposing. Sci Rep. 2018;8(1):975. doi: 10.1038/s41598-017-18457-w
   PubMedGoogle Scholar
• Porto R, Mengarda AC, Cajas RA, et al. Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni. Pharm Basel Switz. 2021;14(7):686. doi: 10.3390/ph14070686
   Google Scholar
• Guidi A, Prasanth Saraswati A, et al. (+)-(R)- and (-)-(S)-perhexiline maleate: Enantioselective synthesis and functional studies on schistosoma mansoni larval and adult stages. Bioorg Chem. 2020;102:104067. doi: 10.1016/j.bioorg.2020.104067
   PubMed Web of Science ®Google Scholar
• Neves BJ, Braga RC, Bezerra JCB, et al. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of schistosoma mansoni. Sripa B, editor. PLoS Negl Trop Dis. 2015;9:e3435. doi: 10.1371/journal.pntd.0003435
   PubMed Web of Science ®Google Scholar
• Roquini V, Mengarda AC, Cajas RA, et al. The existing drug nifuroxazide as an antischistosomal agent: In Vitro , in vivo , and in silico studies of macromolecular targets. Microbiol Spectr. 2023;11(4):e0139323. doi: 10.1128/spectrum.01393-23
   PubMed Web of Science ®Google Scholar
• Rennar GA, Gallinger TL, Mäder P, et al. Disulfiram and dithiocarbamate analogues demonstrate promising antischistosomal effects. Eur J Med Chem. 2022;242:114641. doi: 10.1016/j.ejmech.2022.114641
   PubMed Web of Science ®Google Scholar
• Tomiotto-Pellissier F, Miranda-Sapla MM, Machado LF, et al. Nanotechnology as a potential therapeutic alternative for schistosomiasis. Acta Trop. 2017;174:64–71. doi: 10.1016/j.actatropica.2017.06.025
   PubMed Web of Science ®Google Scholar
• Abd El Wahab WM, El-Badry AA, Mahmoud SS, et al. Ginger (Zingiber officinale)-derived nanoparticles in Schistosoma mansoni infected mice: hepatoprotective and enhancer of etiological treatment. PLoS Negl Trop Dis. 2021;15:e0009423. doi: 10.1371/journal.pntd.0009423
   PubMed Web of Science ®Google Scholar
• Vale N, Gouveia MJ, Gärtner F. Current and novel therapies against helminthic infections: the potential of antioxidants combined with drugs. Biomolecules. 2020;10(3):350. doi: 10.3390/biom10030350
   PubMed Web of Science ®Google Scholar
• Gouveia MJ, Brindley PJ, Rinaldi G, et al. Combination Anthelmintic/Antioxidant activity against Schistosoma Mansoni. Biomolecules. 2019;9(2):54. doi: 10.3390/biom9020054
   PubMed Web of Science ®Google Scholar
• Gouveia MJ, Brindley PJ, Azevedo C, et al. The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni. Parasites Vectors. 2019;12(1):309. doi: 10.1186/s13071-019-3566-9
   PubMedGoogle Scholar
• El-Beshbishi SN, Saleh NE, Abd El-Mageed SA, et al. Effect of omega-3 fatty acids administered as monotherapy or combined with artemether on experimental schistosoma mansoni infection. Acta Trop. 2019;194:62–68. doi: 10.1016/j.actatropica.2019.02.027
   PubMed Web of Science ®Google Scholar
• You H, Mayer JU, Johnston RL, et al. CRISPR/Cas9-mediated genome editing of schistosoma mansoni acetylcholinesterase. FASEB J Off Publ Fed Am Soc Exp Biol. 2021;35:e21205. doi: 10.1096/fj.202001745RR
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan G, Coghlan A, Driguez P, et al. Large CRISPR-Cas-induced deletions in the oxamniquine resistance locus of the human parasite schistosoma mansoni. Wellcome Open Res. 2021;5:178. doi: 10.12688/wellcomeopenres.16031.2
   PubMedGoogle Scholar
• Du X, McManus DP, French JD, et al. Lentiviral Transduction-based CRISPR/Cas9 Editing of Schistosoma mansoni Acetylcholinesterase. Curr Genomics. 2023;24:155–170. doi: 10.2174/1389202924666230823094608
   PubMed Web of Science ®Google Scholar
• Kalinna BH. Programming schistosomes - a crisper approach to transgenesis. Trends Parasitol. 2023;39:896–897. doi: 10.1016/j.pt.2023.09.003
   PubMed Web of Science ®Google Scholar
• Alazmi M. Molecular modeling and docking of aquaporin inhibitors to reveal new insights into schistosomiasis treatment. Curr Comput Aided Drug Des. 2021;16:772–785. doi: 10.2174/1573409915666191003124947
   Web of Science ®Google Scholar
• Whatley KCL, Padalino G, Whiteland H, et al. The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets. LoVerde PT, editor. PLoS Negl Trop Dis. 2019;13:e0007693. doi: 10.1371/journal.pntd.0007693
   PubMed Web of Science ®Google Scholar
• Lancelot J, Caby S, Dubois-Abdesselem F, et al. Schistosoma mansoni sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis. 2013;7(9):e2428. doi: 10.1371/journal.pntd.0002428
   PubMed Web of Science ®Google Scholar
• Neves B, Andrade C, Cravo P. Natural products as leads in schistosome drug discovery. Molecules. 2015;20(2):1872–1903. doi: 10.3390/molecules20021872
   PubMed Web of Science ®Google Scholar
• Kang N, Shen W, Gao H, et al. Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis. Molecules. 2018;23(6):1431. doi: 10.3390/molecules23061431
   PubMed Web of Science ®Google Scholar
• Mitsui Y, Miura M, Kato K. In vitro effects of febrifugine on Schistosoma mansoni adult worms. Trop Med Health. 2020;48(1):42. doi: 10.1186/s41182-020-00230-x
   PubMed Web of Science ®Google Scholar
• Duguet TB, Glebov A, Hussain A, et al. Identification of annotated bioactive molecules that impair motility of the blood fluke schistosoma mansoni. Int J Parasitol Drugs Drug Resist. 2020;13:73–88. doi: 10.1016/j.ijpddr.2020.05.002
   PubMed Web of Science ®Google Scholar